A new biological investigational medicinal product for the treatment of osteoarthritis
HAS2021 orthopedic injection
- First drug of a type on the EU market
- Ready & easy to use
- Of the shelf 2 years
- 100% biological
- No side effects
- High efficacy
Mechanism of action
Based on our more than 10 years of research on placenta tissue, we developed a human amniotic membrane platform (HAM platform), with patented technology AmniPur®. The new drug candidate is based on our invention of how to protect a wide range of bioactive molecules like growth factors and cytokines in their original structure, supporting cells differentiation in the affected region and so cause:
- fast regeneration
- decrease of pain
- reduction of inflamatory
- supporting healing (low imunogenicity)
Target
The aim is clinical development of the Novel Osteoarthrosis Symptoms Drug, which significantly and immediately decreases pain in joints affected area, simultaneously replacing opioids, improving joint mobility, and reducing inflammation.
Medical Problem
16% of the European population suffer from Osteoarthritis. Two and half millions of them get TEP replacement/year with a cost of EUR 85B+ a year. In the past 5 years, the number of surgical operations in the endoprosthesis has increased by 80%. Rejection reaction or manifestation of hypersensitivity to the implant material is observed in 6 – 30% of cases of surgical intervention. The immune reaction is one of the causes of complications of bone tissue on implants.
Source: Juniper Online Journal of Orthopedic & Orthoplastic Surgery, Link
USA is the number one consumer of narcotic drugs, with 40 240 defined daily dosages of opioids per million inhabitants per day. In second place is Germany with 28 862 defined daily dosages per 1 million inhabitants, followed by Canada with 26 029. The Netherlands is in ninth place, with 16 114 defined daily dosages per 1 million inhabitants.
Source: Data from the 2018 report by the International Narcotics Control Board, Link
Media
Napsali o nás